Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1346-8138.17902 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Screening the Irish Marine Biorepository Identifies a New Bryostatin Analog as Potent Inhibitor of Activated B-Cells Diffuse Large B-Cell Lymphoma.
Chembiochem
September 2025
School of Biological and Chemical Sciences, Ryan Institute, University of Galway, University Road, Galway, H91 TK33, Ireland.
Activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL) is an aggressive cancer with poor response to standard chemotherapy. In search of new therapeutic leads, a library of 435 fractions prepared from the Irish marine biorepository was screened against 2 ABC-DLBCL cell lines (TMD8 and OCI-Ly10) and a non-cancerous control cell line (CB33). Active fractions are prioritized based on potency and selectivity.
View Article and Find Full Text PDFInflammatory gene expression profile of oral plasmablastic lymphoma.
Virchows Arch
September 2025
Department of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas Gerais, Minas Gerais, Av. Antônio Carlos, Pampulha, Belo Horizonte, 31270-901, Brazil.
Plasmablastic lymphoma (PBL) is a rare and aggressive non-Hodgkin lymphoma with a poor prognosis and short survival rates. It is classified as a large B-cell lymphoma subtype, but carries a plasmacytic immunophenotype. Therefore, PBL has pathogenetic overlaps with diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) and plasma cell neoplasms (PCNs).
View Article and Find Full Text PDFDrug Delivery and Binding in a Tissue with Irregularly Shaped Binding Regions.
Pharm Res
September 2025
Mechanical and Aerospace Engineering Department, University of Texas at Arlington, 500 W First St, Rm 211, Arlington, TX, 76019, USA.
Objective: A fundamental understanding of drug diffusion and binding processes is critical for the design and optimization of a wide variety of drug delivery devices. Most of the past literature assume binding to occur uniformly throughout the tissue, or, at best, in specific layers of a multilayer tissue. However, in many realistic scenarios, such as in cancer-targeting drugs, drug binding occurs in discrete irregularly shaped regions.
View Article and Find Full Text PDFValidation of Cure Assumptions when Analyzing ZUMA-7 Follow-up Data of Axicabtagene Ciloleucel and Standard of Care Therapy in Second-Line Relapsed/Refractory Large B-cell Lymphoma.
Transplant Cell Ther
September 2025
H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Background: ZUMA-7 is the largest randomized controlled trial (RCT) for chimeric antigen receptor (CAR) T-cell therapy, which compared axicabtagene ciloleucel (axi-cel) to historical standard of care (HSoC) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). Both arms of ZUMA-7 contained potentially curative treatments; however, differences in the treatment completion rate and timing to receive definitive treatment led to differences in the extent and timing of cure. Mixture cure modeling (MCM) has been suggested as a superior method in designing and powering clinical studies of curative therapies but also for extrapolation of long-term outcomes in simulation studies.
View Article and Find Full Text PDFIntegrating the knowledge, attitudes, and practices (KAP) framework with product packaging perceptions: THC products and college students.
J Am Coll Health
September 2025
Hubbard School of Journalism and Mass Communication, University of Minnesota, Minneapolis, Minnesota, USA.
: An evolving THC product marketplace is diffusing through college campuses. It is essential to understand college students' THC knowledge, attitudes, practices and product packaging perceptions to identify campus health education and messaging strategies. : Participants were 30 undergraduate college students at a large-midwestern, public university.
View Article and Find Full Text PDF